We invite you to participate in the GenScript Biotech Global Forum in London, where we will explore the future of cell and gene therapies.
2 min read
Join the GenScript Biotech Global Forum in London to Navigate the Future of Cell and Gene Therapies.
WellnessNewsph | GenScript Biotech Global Forum in London | PISCATAWAY, N.J– The global cell and gene therapy (CGT) industry is experiencing significant growth due to advancements in life sciences and investments from capital markets. To support this sector, GenScript is organizing the GenScript Biotech Global Forum, bringing together scientists, experts, investors, and regulators to discuss key trends in cell and gene therapy.
For more information, please visit the forum website or use the QR code/link provided to register with code GSOM for a free pass.
The GenScript Biotech Global Forum will be held in London on November 20, coinciding with the Jefferies London Healthcare Conference. The theme of this year’s forum is “Unlock the Full Potential of Cell and Gene Therapies,” focusing on collaboration among industry leaders to address challenges and opportunities in the CGT landscape.
Highlights of the agenda include keynote speeches, panel discussions on innovation in CGT and mRNA vaccines, addressing CMC challenges, insights from investors, and presentations from renowned scholars and industry leaders. The event aims to inspire collaboration and impact in the field of cell and gene therapy.
The forum will feature discussions on the future of CGT, multiple cell therapy technologies in development, gene therapy, mRNA vaccines, and challenges in developing and manufacturing CGT products. Keynote speakers include prominent figures in the field, sharing insights and life-saving stories related to CAR-T therapy.
Investment potential in the CGT industry will also be explored, addressing challenges in returns, regulatory hurdles, and manufacturing complexities. The forum will provide investment insights to help attendees understand the potential impact of CGT therapies and secure long-term returns as therapies progress towards commercialization.
Nov. 13, 2024 | PRNewswire |
